Noradrenergic mediation of experimental cerebrovascular spasm.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001488:Basilar Artery / Q000187:drug effects / Q000294:innervation*; D001949:Bretylium Compounds / Q000494:pharmacology; D000882:Haplorhini; D002546:Ischemic Attack, Transient; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013562:Sympathectomy; D014439:Tyramine / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology; D014666:Vasomotor System; D014711:Vertebral Artery / Q000187:drug effects / Q000294:innervation*
D000317:Adrenergic alpha-Antagonists; D001949:Bretylium Compounds; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D009638:Norepinephrine; D014439:Tyramine